Long noncoding RNA MALAT1 may be a prognostic biomarker in IDH1/2 wild-type primary glioblastomas

• Published in: Biomolecules & biomedicine 2020-02, Vol.20 (1), p.63-69
• Main Authors: Argadal, Omer Gokay, Mutlu, Melis, Ak Aksoy, Secil, Kocaeli, Hasan, Tunca, Berrin, Civan, Muhammet Nafi, Egeli, Unal, Cecener, Gulsah, Bekar, Ahmet, Taskapilioglu, Mevlut Ozgur, Tekin, Cagla, Tezcan, Gulcin, Tolunay, Sahsine
• Format: Article
• Language: English
• Subjects: Adult; Aged; biomarker; Biomarkers, Tumor - metabolism; Brain Neoplasms - genetics; Brain Neoplasms - metabolism; Development and progression; Female; Genetic aspects; Glioblastoma - genetics; Glioblastoma - metabolism; Glioblastoma multiforme; Health aspects; Humans; IDH1/2; Isocitrate Dehydrogenase - genetics; Long noncoding RNA; MALAT1; Male; Middle Aged; Mutation - genetics; Physiological aspects; primary glioblastoma; Prognosis; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Long Noncoding - genetics; RNA, Long Noncoding - metabolism; RNA, Messenger - metabolism
• ISSN: 1512-8601; 2831-0896; 1840-4812; 2831-090X
• DOI: 10.17305/bjbms.2019.4297

Primary glioblastoma (GB) is the most aggressive type of brain tumors. While mutations in isocitrate dehydrogenase (IDH) genes are frequent in secondary GBs and correlate with a better prognosis, most primary GBs are IDH wild-type. Recent studies have shown that the long noncoding RNA metastasis associated lung adenocarcinoma transcript-1 (MALAT1) is associated with aggressive tumor phenotypes in different cancers. Our aim was to clarify the prognostic significance of MALAT1 in IDH1/2 wild-type primary GB tumors. We analyzed IDH1/2 mutation status in 75 patients with primary GB by DNA sequencing. The expression of MALAT1 was detected in the 75 primary GB tissues and 5 normal brain tissues using reverse transcription quantitative PCR (RT-qPCR). The associations between MALAT1 expression, IDH1/2 mutation status, and clinicopathological variables of patients were determined. IDH1 (R132H) mutation was observed in 5/75 primary GBs. IDH2 (R172H) mutation was not detected in any of our cases. MALAT1 expression was significantly upregulated in primary GB vs. normal brain tissues (p = 0.025). Increased MALAT1 expression in IDH1/2 wild-type primary GBs correlated with patient age and tumor localization (p = 0.032 and p = 0.025, respectively). A multivariate analysis showed that high MALAT1 expression was an unfavorable prognostic factor for overall survival (p = 0.034) in IDH1/2 wild-type primary GBs. High MALAT1 expression may have a prognostic role in primary GBs independent of IDH mutations.